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Objective: To evaluate the frequency of HLA class I and II alleles associated with traditional 
forms of inflammatory arthritis (IA) in patients with immune checkpoint inhibitor (ICI) induced 
IA as compared to population controls.  
Methods: High-resolution HLA typing was performed on 27 patients with ICI-induced IA and 
726 healthy controls. Genotyping at the shared epitope (SE) locus (HLA DRB1) was performed 
on 220 rheumatoid arthritis (RA) cases. Allele-positivity rates and frequency of having at least 
one SE allele were compared using Fisher’s exact test between ICI-induced IA and healthy 
controls. Frequency of having at least one SE allele was also compared between ICI-induced IA 
and RA cases.  
Results: Twenty-six patients with ICI-induced IA were of European descent, and one was 
African American. In those 26 patients, 16 (61.5%) had at least one SE allele, significantly 
different from healthy controls of European descent, in whom 299 (41.2%) had at least one SE 
allele (OR 2.3, p=0.04).  The allele-positivity rate of DRB1*04:05 was also higher in the ICI-
induced IA group. The ICI-induced IA population and RA patients of European descent did not 
differ in frequency of having at least one SE allele, but ICI-induced IA patients were more likely 
to be autoantibody-negative for rheumatoid factor and anti-cyclic citrullinated peptide 
antibodies.  
Conclusion: Patients with ICI-induced IA of European descent were more likely to have at least 
one SE allele than healthy controls. Further studies are needed to validate these findings and 
investigate whether a unique immunogenetic framework increases risk for different immune 
related adverse events. 
Introduction 
Class I and II human leukocyte antigen (HLA) alleles are important genetic risk factors for a 
variety of autoimmune diseases1. Associations with particular HLA alleles have informed models 
of pathogenesis for autoimmunity, such as in RA, where increased presentation of citrullinated 
antigens by HLA class II shared epitope (SE) is hypothesized as relevant to underlying immune 
biology2.  
Immune-related adverse events (irAEs) from immune checkpoint inhibitor (ICI) therapy can be 
considered novel immune mediated diseases.  ICIs, used in the treatment of a variety of 
malignancies, block negative costimulatory molecules, leading to increased immune activation3. 
As a result of activation of T cells and downstream effects, a variety of inflammatory syndromes 
known as irAEs can occur. Rheumatic irAEs include inflammatory arthritis (IA), sicca 
syndrome, vasculitis, myositis, and scleroderma4 5. IA appears to be the most common rheumatic 
irAE, with prevalence estimates of 5% or higher6.  
Although IA is a fairly common side effect of ICI therapy, the majority of treated patients do not 
develop this adverse event. Also, a wide range of tumor types in patients with ICI-induced IA 
have been reported7. This raises the intriguing hypothesis that a predisposing genetic factor may 
influence which patients develop IA due to ICI treatment. 
ICI-induced IA shares some important similarities to classic forms of inflammatory arthritis. 
Patients can have small joint polyarthritis, similar to rheumatoid arthritis (RA), and can have 
early erosive disease8. There are key differences, however, that suggest a separate immune 
pathogenesis from RA. First, patients are not predominantly female. Second, most patients lack 
traditional autoantibodies, rheumatoid factor (RF) and anti-cyclic citrullinated peptides (CCP). 
Additionally, patients may have features more consistent with spondyloarthritis such as 
enthesitis, reactive arthritis with conjunctivitis and urethritis, or inflammatory back pain7.  
In this pilot study, we aimed to evaluate whether class I and II HLA alleles that are associated 
with classic forms of inflammatory arthritis were more prevalent in patients with ICI-induced IA 
when compared to healthy population controls. We also explored other potential HLA 
associations with complete high-resolution typing of the HLA-A, -B, -C, -DRB1 and -DQB1 
loci.  
Patients and Methods 
Inclusion and exclusion criteria:  
Patients over the age of 18 with rheumatologist-confirmed ICI-induced IA were included in the 
study if they had a DNA sample available for analysis. Patients with preexisting systemic 
autoimmune disease before ICI treatment were excluded.  
Healthy controls were identified from potential bone marrow donors of European descent who 
had high resolution HLA typing performed at our institution.  
Patients with physician-diagnosed RA (also of European descent) were drawn from a 
longitudinal cohort of patients followed for research at our institution and were included if they 
had a DNA sample available for analysis.  
Demographic and clinical data: 
Information on demographics, oncologic history, ICI treatment, and autoantibodies is collected 
as a part of an ongoing prospective cohort study of patients with ICI-induced IA. This study was 
approved by the Johns Hopkins Institutional Review Board (IRB # 00035182) and patients 
signed informed consent in order to participate. 
HLA typing:  
High resolution HLA typing was performed at the CLIA-certified Immunogenetics Laboratory at 
John Hopkins University by NGS using the TruSight HLA Sequencing Panel and the MiSeq 
System (illumina®, San Diego, CA). HLA types were assigned using the Assign TruSight HLA 
Analysis software. HLA- DRB1*01:01, 01:02, 04:01, 04:04, 04:05, 04:08, 10:01, 14:02 were 
designated as SE alleles9 10. 
Statistical analysis:  
The frequency of having at least one SE allele was compared between the ICI-induced IA group 
and healthy controls and between the ICI induced IA group and RA cases.  The statistical 
assessment was made on Stata v.14 (StataCorp LLC, College Station, TX, USA) using Fisher's 
exact test. P-values, odds ratios (OR) and 95% confidence intervals (CI) were also obtained. At 
each of the HLA-A, -B, -C, -DRB1 and -DQB1 loci, allele-positivity rates for the four-digit HLA 
alleles were also compared between cases and controls. Only the top 25 most frequent alleles at 
each locus were compared, and the rest were grouped together for analysis. Given the 
exploratory nature of this study, no adjustment for multiple comparison was applied.  
Results 
Demographics, oncologic history, and clinical features of ICI-induced IA: Twenty-seven patients 
with ICI-induced IA were included. The average age was 60.2 (SD 12.1) years, and 12 patients 
(44.4%) were female. Melanoma was the most common tumor type (N=9), followed by non-
small cell lung cancer (N=6). Other tumor types were renal cell carcinoma, basal cell carcinoma, 
squamous cell carcinoma, Merkel cell carcinoma, colon cancer, endometrial cancer, esophageal 
cancer, breast cancer, and mycosis fungoides (Supplementary Table 1). Twenty-six patients were 
of self-identified European descent, and one was African-American. Nine patients were treated 
with anti-PD-1/CTLA-4 combination therapy, and 18 patients were treated with anti-PD-1 or 
PD-L1 monotherapy (with or without an investigational agent, e.g. anti-CD73, anti-LAG3).  
Most patients lacked autoantibodies traditionally seen in RA; two were positive for RF (7.4%) 
and two were positive for anti-CCP antibodies (7.4%).  
HLA allele frequencies compared to population controls:  For this analysis, only the 26 patients 
of European descent were included. First, SE alleles were grouped together and the probability of 
having at least one SE allele was compared. In ICI-induced IA, 16 (61.5%) had at least one SE 
allele, while 299 (41.2%) of the population control group had at least one SE allele (OR 2.3, 
p=0.04).  Next, class I and II alleles known to be associated with traditional forms of IA (i.e. RA, 
psoriatic arthritis, ankylosing spondylitis) were evaluated. These included the DRB1 SE alleles 
(analyzed individually), B*08:01, B*15:01, B*27:05, C*06:02, and DRB1*03:0111-13. When 
individual alleles were examined for associations, some showed frequency deviations in cases 
with ICI-induced IA (Table 1). HLA DRB1*04:05 was enriched in the ICI-induced IA 
population (OR 8.6, p=0.04). Also included in Table 2 are associations for other individual HLA 
alleles not increased in traditional forms of IA, but with p-values approaching statistical 
significance (Table 1). There were trends toward higher prevalence of HLA A*03:01 (OR 2.2, 
p= 0.07), HLA B*52:01(OR 5.0, p=0.08) and HLA C*12:02 (OR 5.2, p=0.07) in ICI-induced IA. 
Patients with ICI-induced IA had a trend toward lower prevalence of DQB1*03:01 (OR 0.4, p= 
0.06). 
Within the group of ICI-induced IA patients, we evaluated whether clinical characteristics differed 
between patients with and without SE allele. Interestingly, some clinical features were only seen in 
patients lacking SE alleles. Specifically, inflammatory back pain, trigger fingers, prominent 
enthesitis and the case of reactive arthritis were seen in patients without SE alleles. None of these 
features were seen in the SE positive group. Small joint involvement including the small joints of 
hands and wrists, typically thought of as RA-like, was seen in those with and without SE alleles.  
Comparison of ICI-induced IA to RA population:  The probability of having at least one SE allele 
did not differ between patients of European descent with ICI-induced IA and RA patients of 
European descent (Table 2). There was a trend toward the RA patients being more likely to be 
homozygous for SE alleles, with 23.6% of RA cases being homozygous versus just 7.7% of ICI-
induced IA (p=0.15). There were significant differences in RF and anti-CCP positivity (Table 2). 
There were no patients with ICI-induced IA who were positive for both RF and anti-CCP 
antibodies, as compared to the RA population, where 49.3% were double positive. 
Discussion 
In this study of high-resolution HLA typing in ICI-induced IA, patients of European descent 
were more likely to be positive for SE alleles than population controls. There were also 
suggestions of other HLA allelic associations with ICI-induced IA. There was not a significant 
difference in prevalence of SE between patients with ICI-induced IA and those with RA of 
European descent. As previously shown, patients with ICI-induced IA were unlikely to have RF 
or anti-CCP antibodies7 14 15, and this was significantly different from the RA comparator 
population.  
This is one of the first studies to evaluate immunogenetics in patients who develop an irAE due 
to ICI therapy. A smaller study of acute onset type 1 diabetes due to anti-PD-1 therapy showed 
four out of five patients had HLA subgroups DRB01* 03 or 04, which are associated with type 1 
diabetes risk in the general population16. Another study of patients with metastatic melanoma 
treated with ipilimumab suggests that having CTLA-4 gene variant 1661A>G may predispose 
patients to developing endocrine irAEs17. These data evaluated with the present study suggest 
that a patient’s immunogenetic framework may increase the risk for developing irAEs like IA 
due to ICI therapy. This pilot study is hypothesis-generating for future genetic studies in irAEs. 
That SE appears to be enriched in this population was a surprising finding, given this population 
is mostly anti-CCP negative. Two patients with RA-like ICI-induced IA have been previously 
reported to have HLA-DRB1*01:01, one of whom was positive for anti-CCP18. While 
seronegative RA has been found to be associated with SE19, potential mechanisms underlying 
this are less clear. The trends observed toward higher prevalence of several class I alleles are also 
intriguing given associations of various class I alleles with ankylosing spondylitis, peripheral 
spondyloarthritis, and psoriatic arthritis. Certain clinical features in subsets of patients with ICI-
induced IA such as enthesitis, reactive arthritis-like presentation, and inflammatory back pain are 
seen in spondyloarthritis. Interestingly, there was no association with HLA B27, the allele most 
strongly associated with ankylosing spondylitis. This may suggest more similarity with 
peripheral spondyloarthritis or psoriatic arthritis in pathogenesis, rather than ankylosing 
spondylitis. 
Our study also found that HLA B*52:01 and C*12:02 may be associated with ICI-induced IA. 
Interestingly in the Japanese population, the HLA-B*52:01-C*12:02 haplotype has been 
associated with ulcerative colitis and Takayasu’s arteritis20 and HLA-C*12:02 has been 
associated with late-onset psoriasis21, suggesting potential relevance of these alleles to the 
development of autoimmune disease.  
With increasing evidence that tumor response to ICIs is improved in patients who develop 
irAEs22-24, there may be shared genetic associations between response and toxicity. HLA typing 
and response to ICIs was recently evaluated in a large study of patients with melanoma and non-
small cell lung cancer; both patient and tumor HLA class I genotypes influenced tumor response 
to ICI therapy25. Specifically, patients with the HLA-B44 supertype had extended survival, while 
HLA-B62 supertype was associated with worse outcomes. Further genetic investigations could 
evaluate tumor response and irAE development concurrently. 
The study was limited primarily by sample size, which was due to the naturally rare occurrence 
of ICI-induced IA at a single institution. As a result, smaller effect sizes were unlikely to be 
detected. Also, the cases of ICI-induced IA were not entirely clinically homogenous, which 
could lower the statistical power of detecting an association. When a larger sample is available, it 
may be useful to look at groups by pattern of joint involvement or other clinical features to see if 
differing associations exist by subgroup (e.g. whether those with enthesitis have differing HLA 
associations from those with small joint polyarthritis or whether those with multiple irAEs have 
differing HLA associations versus patients with ICI-induced IA alone). It will also be 
informative to study HLA associations in a broader group of ICI-treated patients to define 
whether these alleles are risk factors for ICI-induced IA or other types of irAEs. 
In summary, we observed a potential risk association between the presence of SE alleles and ICI-
induced IA in this pilot study of high-resolution HLA typing. Larger studies are needed to 
confirm this association and to examine whether distinct HLA alleles associate with unique 
phenotypes of ICI induced IA.  
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Key messages 
- Shared epitope alleles were more common in immune checkpoint inhibitor-induced 
inflammatory arthritis than in population controls 
- The immune checkpoint inhibitor-induced inflammatory arthritis population did not differ from 
RA patients in frequency of having at least one shared epitope allele 
- A patient’s immunogenetic framework may influence the development of immune related 
adverse events
Table 1: Comparison of allele-positivity rates for select HLA class I and II alleles and 
prevalence of having at least one SE allele in ICI-induced IA vs population controls of European 
descent 
HLA allele/s Odds ratio (95% CI) ICI-induced IA vs. 
controls  
p-value* 
A*03:01 2.2 (0.9, 5.1)  0.07 
B*08:01 0.9 (0.3, 2.6) 0.56 
B*15:01 2.2 (0.7, 5.9)  0.12 
B*27:05 0.6 (0.0, 4.0) 1.00 
B*52:01 5.0 (0.5, 24.1) 0.08 
C*06:02 0.9 (0.3, 2.7) 1.00 
C*12:02 5.4 (0.6, 26.8) 0.07 
DQB1*03:01 0.4 (0.1, 1.1) 0.06 
DRB1*03:01 1.1 (0.4, 2.9) 0.81 
DRB1*04:05 8.6 (1.7, 43.4) 0.04 
 
At least 1 SE allele 2.3 (1.0, 5.1)  0.04 
*p-values < 0.05 significant (bold) 
 
Table 2: Shared epitope in European descent subset of ICI-induced IA compared to ethnically 
matched RA controls  





Positive for SE (at 
least 1 allele) 
16 (61.5%) 145 (65.9%) 0.66 
Number of shared 
epitope alleles 
Two alleles: 2 (7.7%) 
One allele: 14 (53.8%) 
Zero allele: 10 (38.5%) 
Two alleles: 52 (23.6%) 
One allele: 93 (42.3%) 
Zero allele: 75 (34.0%) 
0.15 
CCP positive 2 (7.7%) 142 (64.6%) <0.01 
RF positive 2 (7.7%) 122/215 (56.7%) <0.01 
RF and CCP double 
positive 
0 (0%)  106/215 (49.3%)  <0.01 
*Fisher’s exact test. CCP: anti-cyclic citrullinated peptide antibodies; RF: rheumatoid factor.  
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Supplementary Table 1: Demographic and Clinical Features of Patients with ICI-induced IA 
Patient Sex Age Tumor type ICI Regimen Autoantibodies SE Present # SE Alleles Clinical features of IA 
1 Female 45 Melanoma PD-1/CTLA-4 None Yes 1 Initial knee pain and swelling; additive course with 
wrists, fingers, shoulders, elbows 
2 Male 35 Melanoma PD-1/CTLA-4 None No 0 Reactive arthritis: urethritis, conjunctivitis, knee and 
ankle swelling 




None No 0 Wrist, shoulders, fingers involved. Significant 
tenosynovitis on US.  
4 Female 53 Melanoma PD-1/CTLA-4 None No 0 Knees and shoulders initially, then PIPs 
5 Male 59 Basal cell PD-1/CTLA-4 None Yes 1 Wrists, ankles, MCPs, PIPs 
6 Male 59 NSCLC PD-1 None No 0 Elbows, shoulders, PIPs, MCPs 
7 Female 73 Mycosis 
Fungoides 
PD-1 Low + CCP Yes 1 Knees, then PIPs, MCPs, and wrists  
8 Male 59 Melanoma PD-1/CTLA-4 None Yes 1 Swelling and pain in shoulder (unilateral), found to 
have resorptive bone lesion; then mild arthritis in 
MCPs, PIPs  
9 Male 82 Merkel cell PD-1 High + RF Yes 1 Swelling in wrist first, then pain and stiffness in 
shoulders and hips 
10 Female 59 NSCLC PD-1 ANA 1:80 speckled No 0 Knees and ankles 
11 Male 54 NSCLC PD-1 None No 0 Trigger fingers, inflammatory back pain, elbow 
involvement 
12 Female 45 Breast 
cancer 
PD-1 None Yes 1 Swelling in one knee, then shoulders, MCPs, PIPs 
13 Male 58 RCC PD-1/CTLA-4 None Yes 1 Ankle first involved (erosion on MRI), PIPs, elbows 
14 Male 81 NSCLC PD-1 None Yes 2 Shoulders and hips, followed by wrists, MCPs 
15 Male 40 Melanoma PD-1/CTLA-4 Anti-smooth 
muscle  
Yes 1 MCPs, PIPS, MTPs, then plantar fasciitis and elbow 
involvement 
16 Female 68 Basal cell 
 
PD-1 None Yes 2 Wrists, ankles, PIPs and MCPs 
17 Male 68 Esophageal 
 
PD-1 Moderate + RF Yes 1 MCPs, PIPs, wrists, knees 
18 Female 54 Melanoma 
 
PD-1/CTLA-4 None No 0 Knees, ankles, wrist. Trigger fingers. 
 





Yes 1 Shoulders, PIPs, wrists 
20 Male 86 Melanoma 
 
PD-1 None Yes 1 PIPs, MCPs, then shoulders 




Yes 1 Shoulders, knees, PIPs 
22 Male 57 NSCLC PD-1 None No 0 Ankles, wrists, dactylitis of index finger 
23 Female 60 RCC PD-1, then 
PD-1 + anti-
LAG-3 
None Yes 1 Wrists, MCPs, knees 
24 Female 65 Pancreatic 
cancer 
PD-1 Moderate + CCP Yes 1 Shoulders, MCPs, PIPs, wrists 
25* Female 70 NSCLC PD-1 None No 0 Knees, then PIPs, MCPs 
26 Female 67 Colon cancer PD-1 None No 0 PIPs first, then knees, elbows, hips 
27 Male 51 Melanoma PD-1/CTLA-4 None No 0 PIPs, MCPs, Achilles enthesitis, wrists, knees, ankles 
SE: shared epitope; NSCLC: non-small cell lung cancer; RF: rheumatoid factor; CCP: anti-cyclic citrullinated peptide antibodies; ANA: anti-nuclear antibodies; RCC: 
renal cell carcinoma. *: Patient 25 was of African descent, all others of European descent. MCP: metacarpophalangeal joint. PIP: proximal interphalangeal joint. 
MTP: metatarsophalangeal joint. 
 
